Synergistic Apoptosis-Ferroptosis: Oxaliplatin loaded amorphous iron oxide nanoparticles for High-efficiency therapy of orthotopic pancreatic cancer and CA19-9 levels decrease

Authors：Li, Yilong; Wang, Xinlong; Ding, Binbin; He, Cong; Zhang, Can; Li, Jiating; Wang, Haonian; Li, Zhibo; Wang, Gang; Wang, Yongwei; Chen, Hua^*; Ma, Ping'an^*; Sun, Bei^*

Source：Chemical Engineering Journal, 2023, 464: 142690.

DOI：10.1016/j.cej.2023.142690

• Orthotopic pancreatic cancer
• Ferroptosis
• Apoptosis
• Oxaliplatin nanodrug
• CA19-9

Pancreatic cancer is a highly malignant tumor with early metastasis, poor prognosis, and resistant to existing chemotherapy drugs such as oxaliplatin (Oxp). Therefore, a nanodrug of amorphous iron oxide packaged Oxp (AIOoxp) was proposed to achieve a more efficient treatment of orthotopic pancreatic cancer than that of free Oxp. The obtained AIOoxp increased the accumulation of Pt at tumor sites and effectively reduced Oxp-induced systemic toxicity. In addition, the Fe2+/Fe3+ ions released by AIOoxp react with H2O2 through Fenton's reaction and produce a large amount of reactive oxygen species (ROS), which further induce ferroptosis, thus promoting Oxp-induced apoptosis and achieve synergistic tumor therapy. Furthermore, AIOoxp nanoplatforms can signifi-cantly reduce the levels of carbohydrate antigen 19-9 (CA19-9), which is the most important biomarker and promoter of pancreatic cancer, suggesting favorable therapeutic effects and prognosis. Overall, this study pro-vides new insights and solutions for the clinical treatment of pancreatic cancer.

• Institution
  1; 哈尔滨医科大学; 中国科学院